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Intravesical application of Bacillus Calmette-Guerin (BCG) immunotherapy is a proven and commonly recognised treatment in reducing both progression and recurrence of urothelial bladder cancer. [1] [2] [3] Following transurethral resection of bladder tumour (TURBT), peri-operative instillation of BCG has been reported to result in systemic spread of Mycobacterium bovis (M. bovis) microorganisms to cardiac defibrillators, aortic grafts, and orthopaedic implants. 4, 5 Systemic dissemination of the M. bovis organism used in BCG therapy and subsequent periprosthetic seeding and infection is a rare but serious complication with the potential to cause significant morbidity in those affected.
We report a case of M. bovis seeding to a prosthetic hip replacement, clinically presenting nine months after the intravesical instillation of BCG for the treatment of superficial non-muscular invasive urothelial bladder carcinoma.
Myobacterium bovis peri-prosthetic hip infection with successful prosthesis retention following intravesical BCG therapy for bladder carcinoma
Lucy Ping Aitchison, Viran Jayanetti, Steven T Lindstrom, and Ronald Sekel Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
Case details
An 80-year-old previously active male presented in March 2013 with a cold, painless 10cm diameter fluid-filled mass in the right buttock posterolaterally with no overlying skin changes. This was associated with a one-month history of night sweats (soaking three shirts/night), anorexia, weight loss (6kg in five months), malaise, and fatigue. BCG treatment had been used for his superficial bladder urothelial carcinoma nine months earlier. In 1975, a primary total hip replacement (THR) was implanted, with three subsequent revisions for mechanical failure, with the last being in 2001, following which the patient had full mobility for 11 years.
Following a diagnosis of superficial urothelial carcinoma of the bladder nine years prior to presentation, multiple recurrences required treatment with six-monthly cystoscopies with repeated transurethral resection of bladder tumour (TURBT). Nine months prior to presentation, six well-tolerated rounds of weekly BCG intravesical therapy were administered with no side effects. Two subsequent cystoscopies at six and 12 months postinstillation revealed no tumour recurrence.
On presentation, inflammatory markers were significantly raised with an erythrocyte sedimentation rate (ESR) of 55mm/h (1-30mm/h) and C-reactive protein (CRP) of 64.6mg/L (0-12mg/L). Within a month of presentation, an X-ray of the right hip showed a lysis halo around the acetabular cup ( Figure 1 ) as well as the distal end of the prosthesis ( Figure 2 ). A bony gap had developed from bone resorption presumed to be a result of infection, a change from the nil abnormalities seen four months prior. Nuclear medicine scans (Tc and Ga) revealed soft tissue infection of the right posterolateral buttock, hip joint, and proximal thigh, involving the femoral and acetabular components.
Debridement and washout of the right hip was performed immediately. A large volume (~500cc) of purulent material was evacuated, with pus connecting between the acetabular component and shaft of the femur laterally. The thickened synovial lining was curetted back to normal tissue after removal of all fibrous necrotic material from within the joint. Initial intraoperative cultured specimens from the hip were negative and empirical 1g IV vancomycin bd was commenced. The CRP was reduced to 25mg/L. Two months after presentation polymerase chain reaction (PCR) was positive for Mycobaterium tuberculosis, the day prior to a planned two-stage hip exchange procedure, which was thus cancelled. Rifampicin 600mg, isoniazid 300mg, ethambutol 1.0g, pyrazinamide 2.0g, and pyridoxine 25mg daily was commenced. M. bovis was subsequently cultured; sensitivity testing showing resistance to pyrazinamide. Two further washout procedures of the abscess were performed three and four months after presentation.
Cultures from the second right hip washout three months after presentation grew M. bovis, as well as Staph epidermidis which was treated with two weeks of IV vancomycin, followed by clindamycin long term. Our patient became systemically well at four months from the beginning of treatment. Anti-tuberculous medication was reduced to ethambutol 1.6g, rifampicin 600mg, isoniazid 600mg, and pyroxidine 25mg, three times weekly and ceased 15 months after their commencement.
Further, and what is most remarkable to note, is that his previous bony defects around the femoral shaft and behind the acetabular cup filled in with new bone formation (Figures 3 and 4 ). This is a most integral process in the retention of the prosthesis, its functional viability being dependant on reversal of the loosening. Twenty-seven months from initial presentation, our patient remains systemically well, fully weight bearing and mobile without pain. There is a small 3mm sinus at the hip wound with minimal discharge but no surrounding erythema for which the patient is continuing to take 300mg clindamycin tds for its suppressive effect. There has been no clinical evidence of relapse of the M. bovis infection.
Discussion
The bladder intravesicular application of a live attenuated strain of M. bovis in the form the BCG is now routinely used in the treatment of carcinoma of the bladder and is superior to TURBT alone in preventing tumour recurrence. 1, [6] [7] [8] [9] [10] [11] [12] Localised side effects of BCG intravesical therapy to the bladder, including dysuria, urgency, frequency, and a lowgrade fever are to be expected following treatment and are usually self-limiting within 48 hours. 13 However, systemic complications have the potential, as with this patient, to cause significant morbidity and mortality. [14] [15] [16] BCG bacteraemia was reported by Lamm to occur in 0.4 per cent of 2,602 patients, 7 of which those with prostheses, such as cardiac pacemakers, orthopaedic hardware, or artificial valves, present a theoretically increased risk of bacterial seeding at these sites. [17] [18] [19] Dissemination of bacteria around orthopaedic prostheses is an extremely rare occurrence with only seven cases reported in the literature (Table 1) , with all but one having the original prosthesis removed. [20] [21] [22] [23] [24] [25] [26] While fever is a common side effect of therapy (28 per cent of patients) 27 and may even be associated with improved response to immunotherapy, 28 a temperature lasting more than 48 hours or >39°C is an indication of organism dissemination, and the literature recommends that empirical anti-tuberculous treatment be commenced and further BCG therapy withheld until symptoms have resolved. 7, 14, 29 Immuno-compromising and healing impairing factors such as previous pelvic irradiation, systemic steroid administration, diabetes, and persistent cystitis also need to be considered. 14 With the increased morbidity and mortality associated with revision joint replacement surgery, it is preferable to overcome a BCG infection with non-operative treatment as described in this case; i.e., retention of joint prosthesis with prolonged anti-tuberculous treatment.
The BCG organism is known to be sensitive to antituberculous therapy. 30, 31 There have been five reported cases of successful treatment of prosthetic M. bovis infection post-BCG using revision arthroplasty with employment of at least two anti-tuberculosis drugs. 20, 21, [23] [24] [25] As such, two popular methods of surgical management for prosthetic joint infection were considered:
1. the debridement, antibiotics and implant retention strategy (DAIR); and 2. two-stage implant revision.
In view of the solidly ingrown large prosthetic stem used at the last revision 13 years ago, removal would have been extremely difficult, and a DAIR treatment approach for this case was adopted. This process involves surgical debridement of the joint, antibiotic therapy, and irrigation with retention of the prosthesis while replacing the modular stem ball and cup liner. 32, 33 Due to this combination of surgical management and long-term antibiotic therapy, this strategy allows conservation of the prosthesis with the potential for infection suppression or clearance, a first for the treatment of periprosthetic hip infection post-BCG instillation. 33 On identification of acid-fast bacilli, a regimen of antituberculous drugs must be commenced alongside simultaneous further testing to differentiate between Mycobacterium species and to determine antibiotic sensitivities and resistances, subsequently allowing tailored antibiotic therapy. Furthermore, joint washouts should be considered to decrease the infection burden for the antituberculosis drugs to overcome, thus augmenting drug therapy.
There has been previous consideration of prophylactic antituberculous drugs for patients with prosthetic devices, 17, 34 but in a randomised controlled trial (RCT) of 952 patients, isoniazid was found to be ineffective as prophylaxis, given at three days for each BCG instillation for reducing both local and systemic side effects of BCG therapy. 35 Furthermore, due to the rarity of peri-prosthetic M. bovis infection following BCG therapy and the potential toxicities of antituberculous drug therapy, 15, [36] [37] [38] further research is necessary to determine the risk-to-benefit ratio for prophylaxis.
It is important to be aware that bladder intravesical BCG therapy can disseminate still viable organisms around orthopaedic prosthetic implants, not just pacemakers and aortic plaques. 4, 5 If infection in any of these areas is suspected, it is important to culture not only for common organisms, but also for mycobacteria in these patients, and to order for PCR on cell block tissue for tuberculosis. If positive, further sequencing can lead to determination of M. bovis. Our patient was treated successfully with repeated joint washouts, and anti-tuberculous therapy without removal of the hip replacement implants.
Conclusion
Dissemination of M. bovis from bladder intravesical BCG therapy to prostheses can occur. We present a case of hip prosthesis infection with M. bovis that was successfully treated with anti-tuberculous medication and washouts without the need of prosthesis removal. 
